A Phase II Trial of High Dose Interleukin-2 (HDIL-2) With Recombinant MAGE-A3 Protein Combined With Adjuvant System AS15 (recMAGE-A3 + AS15) in Patients With Unresectable or Metastatic Melanoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Zastumotide (Primary) ; AS15; Interleukin-2
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 20 Apr 2016 Results (n=16) presented at the 107th Annual Meeting of the American Association for Cancer Research
- 07 Apr 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018, according to ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History